Pharmacokinetic modeling of an induction regimen for in vivo combined testing of novel drugs against pediatric acute lymphoblastic leukemia xenografts.
about
Plasma Hsp90 Level as a Marker of Early Acute Lymphoblastic Leukemia Engraftment and Progression in MiceThe glutaminase activity of L-asparaginase is not required for anticancer activity against ASNS-negative cells.Cell and molecular determinants of in vivo efficacy of the BH3 mimetic ABT-263 against pediatric acute lymphoblastic leukemia xenograftsA pre-clinical model of resistance to induction therapy in pediatric acute lymphoblastic leukemiaAKR1C3 is a biomarker of sensitivity to PR-104 in preclinical models of T-cell acute lymphoblastic leukemiaEffective targeting of the P53-MDM2 axis in preclinical models of infant MLL-rearranged acute lymphoblastic leukemia.Cellular intrinsic mechanism affecting the outcome of AML treated with Ara-C in a syngeneic mouse model.Variegated clonality and rapid emergence of new molecular lesions in xenografts of acute lymphoblastic leukemia are associated with drug resistance.A transcriptomic signature mediated by HOXA9 promotes human glioblastoma initiation, aggressiveness and resistance to temozolomideAsparaginase Potentiates Glucocorticoid-Induced Osteonecrosis in a Mouse ModelFunctional genomic screening reveals asparagine dependence as a metabolic vulnerability in sarcomaMLL-Rearranged Acute Lymphoblastic Leukemias Activate BCL-2 through H3K79 Methylation and Are Sensitive to the BCL-2-Specific Antagonist ABT-199.MicroRNAs and Glucocorticoid-Induced Apoptosis in Lymphoid MalignanciesThe anti-CD19 antibody-drug conjugate SAR3419 prevents hematolymphoid relapse postinduction therapy in preclinical models of pediatric acute lymphoblastic leukemia.Targeting connective tissue growth factor (CTGF) in acute lymphoblastic leukemia preclinical models: anti-CTGF monoclonal antibody attenuates leukemia growth.Pharmacogenomic considerations of xenograft mouse models of acute leukemia.A Comprehensive Review on L-Asparaginase and Its Applications.Hyperoside enhances the suppressive effects of arsenic trioxide on acute myeloid leukemia cellsAcute Sensitivity of Ph-like Acute Lymphoblastic Leukemia to the SMAC-Mimetic Birinapant.A novel L-asparaginase with low L-glutaminase coactivity is highly efficacious against both T and B cell acute lymphoblastic leukemias in vivo.Bioluminescence Imaging Enhances Analysis of Drug Responses in a Patient-Derived Xenograft Model of Pediatric ALL.Xenograft-directed personalized therapy for a patient with post-transplant relapse of ALL.
P2860
Q27304789-A7D36BCE-92FC-4959-B16B-88508E26DE09Q33718822-9847B1A2-8292-41DA-8FC4-D68F780ECDD3Q34135333-D171B203-4749-40B9-8EBA-8BE480704366Q34448969-CABD38BE-8E77-4B98-BE97-C09E77E1ED53Q34482552-425B34B5-2013-4DAF-833E-2FA2DC8D9F68Q35178411-0A8E81C4-3FE5-4650-9CDF-3C7E9437C992Q35331086-6D66C67D-DE45-4DB6-B7CC-D6B7C77623C1Q35467835-F25685BB-7C0A-496B-B127-CB222BABE641Q35781382-947A1BA4-1BE5-4E73-8CBF-0823B83E7C54Q35954058-21EB10CD-8628-4A16-944B-574B05B58CA8Q36415118-21F18440-055E-4656-9FA0-BD7313403FEBQ36426910-D4607A43-D1EE-489E-B278-BF5BD796EA6AQ36602853-80E135A1-3889-4989-BEAF-EDD6724403ACQ36745332-C843ADA8-30F3-4490-B018-36B0C79585D8Q37627887-E46B054E-F6A4-41CB-8567-18DDB9E20506Q38061500-E7EFB230-1A2B-421E-8E17-DCB591B12395Q38627854-9B4BB237-3609-485E-8B87-503C991EBB24Q38815001-D161FF36-8F69-43F6-B344-1537F3FEF9C9Q42226188-769BF1C1-BA3C-4DA2-9AFC-C580840C4E48Q49032263-02E6F82D-03B0-4E53-82B5-4C87CF28EA0AQ50209854-BB4F77DB-73C9-4CE9-9B52-DAA7EEEB8FB8Q53100287-9F8752AE-0A56-48B2-BEE4-D9A5593A6135
P2860
Pharmacokinetic modeling of an induction regimen for in vivo combined testing of novel drugs against pediatric acute lymphoblastic leukemia xenografts.
description
2012 nî lūn-bûn
@nan
2012 թուականի Մարտին հրատարակուած գիտական յօդուած
@hyw
2012 թվականի մարտին հրատարակված գիտական հոդված
@hy
2012年の論文
@ja
2012年論文
@yue
2012年論文
@zh-hant
2012年論文
@zh-hk
2012年論文
@zh-mo
2012年論文
@zh-tw
2012年论文
@wuu
name
Pharmacokinetic modeling of an ...... hoblastic leukemia xenografts.
@ast
Pharmacokinetic modeling of an ...... hoblastic leukemia xenografts.
@en
Pharmacokinetic modeling of an ...... hoblastic leukemia xenografts.
@nl
type
label
Pharmacokinetic modeling of an ...... hoblastic leukemia xenografts.
@ast
Pharmacokinetic modeling of an ...... hoblastic leukemia xenografts.
@en
Pharmacokinetic modeling of an ...... hoblastic leukemia xenografts.
@nl
prefLabel
Pharmacokinetic modeling of an ...... hoblastic leukemia xenografts.
@ast
Pharmacokinetic modeling of an ...... hoblastic leukemia xenografts.
@en
Pharmacokinetic modeling of an ...... hoblastic leukemia xenografts.
@nl
P2093
P2860
P50
P1433
P1476
Pharmacokinetic modeling of an ...... phoblastic leukemia xenografts
@en
P2093
Barbara Szymanska
Clinton F Stewart
Daniel Groepper
Hernan Carol
Ingrid Boehm
Natalia L M Liem
Urszula Wilczynska-Kalak
P2860
P304
P356
10.1371/JOURNAL.PONE.0033894
P407
P577
2012-03-29T00:00:00Z